Ozempic Shortage 2026: Who’s Getting It and Who Can’t — and What to Do

The surging demand for semaglutide (Ozempic, Wegovy) has created a shortage that is affecting diabetic patients who need it for blood sugar management and weight-loss patients who want it for obesity treatment. Here’s the current situation.

Where the Shortage Stands in 2026

The FDA removed brand-name semaglutide from its shortage list in late 2024 — but access remains uneven. Many pharmacies still face supply constraints on specific doses, and insurance coverage remains a major barrier for weight-loss use.

Who Gets Priority?

Manufacturer Novo Nordisk has publicly stated that diabetic patients (using Ozempic for its approved indication) should be prioritized over weight-loss patients (using Wegovy). In practice, this means:

• Type 2 diabetes patients have better coverage and supply access
• Non-diabetic obesity patients face more barriers to both supply and insurance coverage

The Compounded Semaglutide Question

During the shortage, compounding pharmacies legally produced semaglutide copies. The FDA has since taken action against many compounders, but the situation is legally complex and rapidly evolving. If you’ve been using compounded semaglutide, consult your prescriber about your options.

What to Do If You Can’t Get It

• Call multiple pharmacies — supply varies dramatically by location
• Ask your doctor about alternative GLP-1 medications (tirzepatide/Mounjaro, liraglutide/Victoza)
• Check manufacturer savings programs: Novo Nordisk offers programs for eligible patients
• Ask about samples from your prescribing doctor’s office

📌 Source: FDA.gov, Novo Nordisk. Drug availability changes rapidly — verify with your pharmacy.